132 related articles for article (PubMed ID: 22996774)
41. [Preventive effect of urinastatin on cisplatin-induced nephrotoxicity].
Kobayashi H; Ishizuka H; Hirashima Y; Ohi H; Demukai H; Moniwa M; Maeda M; Kobayashi T; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1959-64. PubMed ID: 2592819
[TBL] [Abstract][Full Text] [Related]
42. [Associations between Clinical Factors and Acute Renal Failure Due to Cisplatin Combination Chemotherapy for Lung Cancer].
Yamashita K; Yoshino M; Sasaki N; Tanaka Y; Tanaka K; Abe M; Tagawa C; Kawahara F; Kato K; Kaise M; Tanaka H; Chou T
Gan To Kagaku Ryoho; 2015 Nov; 42(11):1379-83. PubMed ID: 26602395
[TBL] [Abstract][Full Text] [Related]
43. Renal tolerance of cisplatin in patients more than 80 years old.
Thyss A; Saudes L; Otto J; Creisson A; Gaspard MH; Dassonville O; Schneider M
J Clin Oncol; 1994 Oct; 12(10):2121-5. PubMed ID: 7931482
[TBL] [Abstract][Full Text] [Related]
44. [Analysis of Renal Toxicity of S-1 plus CDDP Regimen with Short Hydration for Outpatients with Gastric Cancer].
Hasegawa T; Teraoka H; Mori T; Kinoshita H; Nakamoto K; Noda E; Hirakawa K; Ohira M
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2407-2409. PubMed ID: 32156947
[TBL] [Abstract][Full Text] [Related]
45. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
[TBL] [Abstract][Full Text] [Related]
46. High-dose cisplatin in patients with advanced malignancies.
Blumenreich MS; Woodcock TM; Jones M; Richman SP; Gentile PS; Kubota TT; Allegra JC
Cancer; 1985 Mar; 55(5):1118-22. PubMed ID: 4038468
[TBL] [Abstract][Full Text] [Related]
47. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study.
Oka T; Kimura T; Suzumura T; Yoshimoto N; Nakai T; Yamamoto N; Matsuura K; Mitsuoka S; Yoshimura N; Kudoh S; Hirata K
BMC Pharmacol Toxicol; 2014 Dec; 15():70. PubMed ID: 25472655
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
[TBL] [Abstract][Full Text] [Related]
49. Renal toxicity caused by brand-name versus generic cisplatin: a comparative analysis.
Niho S; Yamanaka T; Umemura S; Matsumoto S; Yoh K; Goto K; Ohmatsu H; Ohe Y
Jpn J Clin Oncol; 2013 Apr; 43(4):390-5. PubMed ID: 23444114
[TBL] [Abstract][Full Text] [Related]
50. Early measurement of urinary N-acetyl-β-glucosaminidase helps predict severe hyponatremia associated with cisplatin-containing chemotherapy.
Arakawa Y; Tamura M; Sakuyama T; Aiba K; Eto S; Yuda M; Tanaka Y; Matsumoto A; Nishikawa K
J Infect Chemother; 2015 Jul; 21(7):502-6. PubMed ID: 25851853
[TBL] [Abstract][Full Text] [Related]
51. Comparison of cisplatin-induced nephrotoxicity when using conventional versus short hydration in gastric cancer-a retrospective study.
Aoyama T; Tsunoda T; Kato H; Hagino A; Furutani R; Ito K; Yoshioka H; Nakamura M; Hiraide M; Kawakami K; Kobayashi K; Suzuki K; Ichimura T; Yamaguchi K; Hama T
J Chemother; 2020 May; 32(3):144-150. PubMed ID: 31960769
[TBL] [Abstract][Full Text] [Related]
52. Mannitol for the prevention of cisplatin-induced nephrotoxicity: A retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center.
Williams RP; Ferlas BW; Morales PC; Kurtzweil AJ
J Oncol Pharm Pract; 2017 Sep; 23(6):422-428. PubMed ID: 27352615
[TBL] [Abstract][Full Text] [Related]
53. Cis platine (CDDP) in continuous intravenous ambulatory infusion: a new method of administration.
Benahmed M; Renaux J; Spielman M; Rouesse J
Cancer Drug Deliv; 1986; 3(3):183-8. PubMed ID: 3779603
[TBL] [Abstract][Full Text] [Related]
54. Magnesium depletion in patients receiving cisplatin-based chemotherapy.
Hodgkinson E; Neville-Webbe HL; Coleman RE
Clin Oncol (R Coll Radiol); 2006 Nov; 18(9):710-8. PubMed ID: 17100159
[TBL] [Abstract][Full Text] [Related]
55. Feasibility study of short hydration using oral rehydration solution in cisplatin including chemotherapy of lung cancer.
Sato J; Morikawa N; Nitanai H; Nagashima H; Nihei S; Yamauti K; Kudo K
J Pharm Health Care Sci; 2016; 2():6. PubMed ID: 26949541
[TBL] [Abstract][Full Text] [Related]
56. Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin.
Reece PA; Stafford I; Russell J; Gill PG
J Clin Oncol; 1986 Sep; 4(9):1392-8. PubMed ID: 3746376
[TBL] [Abstract][Full Text] [Related]
57. Metastatic urothelial cancer showing an efficacy by low-dose cisplatin.
Matsuyama H; Yamakawa G; Hirata H
Int J Urol; 2002 May; 9(5):275-7. PubMed ID: 12060442
[TBL] [Abstract][Full Text] [Related]
58. Comparison of cisplatin-induced nephrotoxicity between single-dose and split-dose administration to rats.
Fukushima K; Futatsugi A; Maekawa M; Naito S; Okada A; Sugioka N
Biomed Pharmacother; 2022 Mar; 147():112619. PubMed ID: 34999374
[TBL] [Abstract][Full Text] [Related]
59. Combined floxuridine and cisplatin in a fourteen day infusion. Phase I study.
Lokich J; Anderson N; Bern M; Wallach S; Moore C; Williams D; Umprain V
Cancer; 1988 Dec; 62(11):2309-12. PubMed ID: 2972354
[TBL] [Abstract][Full Text] [Related]
60. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.
Crona DJ; Faso A; Nishijima TF; McGraw KA; Galsky MD; Milowsky MI
Oncologist; 2017 May; 22(5):609-619. PubMed ID: 28438887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
